Skip to main content
. 2021 Apr 2;22(7):3713. doi: 10.3390/ijms22073713

Figure 1.

Figure 1

Fetal hAFS and perinatal hAFS phenotypic evaluation. (A) Representative images of fetal hAFS (f-hAFS, left panel) and perinatal hAFS (p-hAFS, right panel) cultured in vitro in standard conditions; scale bar: 200 µm. (B) Analysis of the senescent marker beta-galactosidase (SA-β-Gal, in blue) via cytochemistry staining on f-hAFS and p-hAFS after 5 passages in culture; representative images are reported in the left panel, scale bar: 200 µm. The corresponding percentage of β-Gal-positive cells/field is reported in the graph in the right panel (f-hAFS: 4.12 ± 0.58% and p-hAFS: 3.88 ± 2.10%; p = 0.1424, n = 3 experiments). (C) Immunophenotype of hAFS expressing CD146 and CD107a mesenchymal markers. Representative flow cytometry plots of f-hAFS and p-hAFS (left panel) and corresponding values referred to double positive CD107a+ CD146+ cells; CD107a+ CD146+ f-hAFS: 63.68 ± 5.82%, * p = 0.016 compared to remaining 36.32 ± 5.82% f-hAFS (Other); CD107a+ CD146+ p-hAFS: 52.07 ± 6.76% with remaining 47.93 ± 56.76% p-hAFS (Other); CD107a+ CD146+ f-hAFS vs CD107a+ CD146+ p-hAFS p = 0.2403, n = 4 experiments. Other: total amount of remaining CD107a− CD146− hAFS, CD107a− CD146+ hAFS and CD107a+ CD146− hAFS. All values are expressed as mean ± s.e.m of independent experiments. SA-β-Gal: Senescence-Associated-β-galactosidase.